|

A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis

RECRUITINGPhase 3Sponsored by Bristol-Myers Squibb
Actively Recruiting
PhasePhase 3
SponsorBristol-Myers Squibb
Started2025-03-13
Est. completion2030-03-06
Eligibility
Age5 Years – 17 Years
Healthy vol.Accepted
Locations7 sites
View on ClinicalTrials.gov →

NCT06869551

Summary

The purpose of this study is to evaluate the drug levels, efficacy, and safety of Deucravacitinib (BMS-986165) in pediatric participants with juvenile psoriatic arthritis.

Eligibility

Age: 5 Years – 17 YearsHealthy volunteers accepted
Inclusion Criteria

* Participants must have been diagnosed with Juvenile Psoriatic Arthritis (JPsA).
* Participants must have at least three joints that are affected by arthritis.
* Participants must have tried at least one type of medicine for JPsA for at least three months, but it didn't work well or caused problems.

Exclusion Criteria

* Participants must not have been diagnosed with JPsA before 5 years of age.
* Participants must not have other types of Juvenile Idiopathic Arthritis (JIA) that aren't JPsA,
* Participants must not have a history of chronic eye inflammation (uveitis), or were diagnosed with uveitis within the last three months.
* Other protocol-defined Inclusion/Exclusion criteria apply.

Conditions2

ArthritisJuvenile Psoriatic Arthritis

Locations7 sites

Local Institution - 0038
Lancaster, California, 93534
Site 0038
Local Institution - 0020
Chicago, Illinois, 60611
Site 0020
Local Institution - 0023
Indianapolis, Indiana, 46202
Site 0023
Local Institution - 0059
North New Hyde Park, New York, 11040
Site 0059
Local Institution - 0065
Cincinnati, Ohio, 45229
Site 0065

Browse More Trials

Arthritis trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.